Please login to the form below

Not currently logged in

Sanofi pulls development of blood cancer drug

Fedratinib linked to brain disorder during clinical trials
Sanofi reception

Sanofi has withdrawn all trials involving the investigational blood cancer drug fedratinib.

The France-based pharma company said the reason to pull fedratinib – also known as SAR302503 – was due to the drug's link to an increased risk of the brain disorder Wernicke's encephalopathy.

The US Food and Drug Administration (FDA) has previously directed Sanofi to put on hold all clinical trials involving fedratinib after some patients involved in the study developed Wernicke's encephalopathy, which can result in eye problems, loss of coordination and memory loss.

However, a subsequent analysis carried out by Sanofi in consultation with the FDA and other experts determined that the benefits posed by the drug did not outweigh its risk, forcing all development to be cancelled and all filing plans to be shelved.

Dr Tal Zaks, head of development and interim head of Sanofi Oncology, explained: “We are deeply disappointed to have to discontinue development of fedratinib, especially given the needs of this difficult-to-treat patient population and the earlier promise shown for this therapy, but patient safety is our top priority and drove this decision.”

Fedratinib – a JAK2 inhibitor - had been in development for several blood cancers that fall under the banner of myeloproliferative neoplasms.

The most advanced indication was myelofibrosis for which the drug had shown positive phase III data and was on course to compete with the likes of Gilead Sciences' CYT387 and Cell Therapeutics/Baxter's pacritinib.

The other blood disorders fedratinib is no longer being investigated for are polycythemia vera and essential thrombocythemia.

Sanofi said that patients currently in fedratinib trials should consult with their doctor to determine the best alternative course of therapy.

Article by
Thomas Meek

18th November 2013

From: Sales, Regulatory



COVID-19 Updates and Daily News

Featured jobs


Add my company

AMICULUM® is an independent global healthcare communications, consulting and learning business with a global team of >220 healthcare communications professionals,...

Latest intelligence

How innovating study sites can improve patient recruitment efficiency
There are so many ways that clinical trials have innovated over the last few years. There is now a larger focus on making trials more patient-centric, more virtualised, and more...
Avoiding A Series of Unfortunate Events: launch lessons from lockdown
Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
6 reasons patients drop out of clinical trials and 6 ways to fix it
If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....